Trial · NCT03439345
Trial comparisons23
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 20 of 23
Download this page as JSON| Comparison | Source |
|---|---|
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants in Subgroup Age ≥60y With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment. | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants in Subgroup With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment, After 1 Year From Randomization | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants in Subgroup Sex - Male With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants With Occurrence of Major Cardiovascular Events (Myocardial Infarction, Stroke, Coronary or Peripheral Revascularisation) | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants in Subgroup - HbA1c ≥70 mmol/Mol With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants in Subgroup - eGFR ≥60 mL/Min/1.73m^2 With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants in Subgroup - Type 1 Diabetes With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants in Subgroup - HbA1c <70 mmol/Mol With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants With the Individual Component of Composite Primary Outcome: Treatment for Diabetic Retinopathy or Maculopathy | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants in Subgroup Sex - Female With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants With The Development of Macular Oedema | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants in Subgroup - Type 2 or Other Type of Diabetes With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants With Occurrence of Non-traumatic Lower Limb Amputations | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants With Referable Maculopathy (Exudates or Blot Haemorrhages Within One Disc Diameter of the Fovea) | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants With the Individual Component of the Composite Primary Outcome: Development of Referable Diabetic Retinopathy or Maculopathy | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants in Subgroup With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment, Within 1 Year of Randomization | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants in Subgroup - HbA1c Unknown With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants in Subgroup Age <60y With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants With Any Progression of Diabetic Retinopathy or Maculopathy Across the NHS Scotland Retinopathy Grading Scale | Trial comparisons |
| Fenofibrate 145 mg vs Placebo Oral Tablet: Number of Participants With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03439345/comparisons